Megestrol acetate in relapsed carcinoma of prostate.
A series of 22 patients with advanced carcinoma of the prostate who had failed first-line hormonal therapy (orchiectomy, stilboestrol, luteinising hormone-releasing hormone agonist) were treated with 160 mg megestrol acetate daily. Treatment was well tolerated, side effects were minimal and 21 patients were evaluable. There were no complete or partial responses, although 8 patients had a good subjective response. In 6 patients the disease was stabilised for 6 to 12 months and there was a 40 to 50% reduction in their prostatic acid phosphatase (PAP) levels. It was concluded that megestrol acetate has a role as second-line hormonal therapy in the management of prostatic carcinoma.
Daniel
F
F
Department of Radiotherapy and Oncology, Plymouth General Hospital.
MacLeod
P M
PM
Tyrrell
C J
CJ
D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D004054:Diethylstilbestrol / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D008535:Megestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; D008535:Megestrol; D019290:Megestrol Acetate